A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Oncotelic Therapeutics, Inc.
OTLC
$14M
Mkt Cap
$0.04
+16.67%
Oncotelic Therapeutics, Inc. (OTLC) has a 5-year average return on invested capital (ROIC) of -88.0%. This is below average and may indicate limited pricing power.
Oncotelic Therapeutics, Inc. (OTLC) has a market capitalization of $15M. It is classified as a small-cap stock.
Oncotelic Therapeutics, Inc. (OTLC) does not currently pay a regular dividend.
Oncotelic Therapeutics, Inc. (OTLC) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Oncotelic Therapeutics, Inc. (OTLC) generated $-1 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Oncotelic Therapeutics, Inc. (OTLC) has a debt-to-equity ratio of 0.97. This indicates moderate leverage.
Oncotelic Therapeutics, Inc. (OTLC) reported earnings per share (EPS) of $-0.02 in its most recent fiscal year.
ITEM 1. BUSINESS Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) (“Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly-owned subsidiaries, Oncotelic, Inc., a Delaware corporation, PointR Data, Inc. (“PointR”), a Delaware corporation, Pet2DAO, Inc., a Delaware corporation; and EdgePoint AI, Inc. (“Edgepoint”), a Delaware Corporation for which there are non-controlling interests, (Oncotelic, Oncotelic Inc., PointR, Pet2DAO and Edgepoint are collectively called the “Company” or “We”).
| Segment | 2023 | % of Total |
|---|---|---|
Service | $0M | 100% |
| Metric | TTM | FY2023 | FY2021 | FY2020 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | - | - | - |
| Net Income | -1.7M | -7.9M | -9.4M | -9.5M | -13M | -8.1M |
| EPS | $0.00 | $-0.02 | $-0.03 | $-0.11 | $-4.67 | $-5.48 |
| Free Cash Flow | 0 | -1.3M | -4.4M | -2.8M | -7.0M | -8.3M |
| ROIC | -2.9% | -56.3% | -54.4% | -80.7% | -108.2% | -140.3% |
| Gross Margin | - | 0.0% | 0.0% | - | - | - |
| Debt/Equity | 1.14 | 0.97 | 0.81 | 0.25 | 0.21 | 0.20 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | - | - | - |
| Operating Income | -689K | -6.6M | -9.1M | -7.6M | -8.3M | -8.1M |
| Operating Margin | 0.0% | 0.0% | 0.0% | - | - | - |
| ROE | -18.4% | -65.2% | -95.2% | -80.7% | -247.0% | -121.1% |
| Shares Outstanding | 441M | 395M | 313M | 379M | 3M | 1M |
| Metric | ||||||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | 0 | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | 0.0% | 0.0% | N/A |
| R&D | 3.5M | 3.6M | 4.3M | 3.7M | 61K | 61K |
| SG&A | 4.7M | 4.7M | 5.0M | 5.5M | 574K | 690K |
| EBIT | -8.1M | -8.3M | -7.6M | -9.1M | -6.6M | -689K |
| Op. Margin | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% |
| Net Income | -8.1M | -13M | -9.5M | -9.4M | -7.9M | -1.7M |
| Net Margin | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% |
| Non-Recurring | 15K | 15K | 0 | 0 | 6.1M | 0 |
| Returns on Capital | ||||||
| ROIC | -140.3% | -108.2% | -80.7% | -54.4% | -56.3% | -2.9% |
| ROE | -121.1% | -247.0% | -80.7% | -95.2% | -65.2% | -18.4% |
| ROA | -97.9% | -205.3% | -40.2% | -39.7% | -26.3% | -5.9% |
| Cash Flow | ||||||
| Op. Cash Flow | -8.3M | -7.0M | -2.8M | -4.4M | -1.3M | -704K |
| Free Cash Flow | -8.3M | -7.0M | -2.8M | -4.4M | -1.3M | 0 |
| Owner Earnings | -9.2M | -7.9M | -5.0M | -5.2M | -2.2M | -1.6M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 357K | 268K | 37K | 10K | 13K | 13K |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 357K | 268K | 37K | 10K | 13K | 13K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 511K | 679K | 2.1M | 763K | 902K | 902K |
| Debt Repayment | 0 | 0 | 0 | 100K | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | N/A | 2.0M | 5.3M | 11M | 9.5M |
| Cash & Equiv. | 4.9M | 7.0M | 474K | 569K | 170K | 818K |
| Long-Term Debt | N/A | N/A | N/A | N/A | 1.9M | 1.9M |
| Debt/Equity | 0.20 | 0.21 | 0.25 | 0.81 | 0.97 | 1.14 |
| Interest Coverage | N/A | N/A | -3.8 | -4.6 | -6.4 | -6.4 |
| Equity | 4.5M | 6.0M | 12M | 8.0M | 12M | 9.1M |
| Total Assets | 5.4M | 7.3M | 24M | 24M | 30M | 28M |
| Total Liabilities | 901K | 1.3M | 11M | 15M | 18M | 20M |
| Intangibles | 191K | 93K | 22M | 22M | 6.0M | 2.8M |
| Retained Earnings | -225M | -239M | -22M | -31M | -34M | -39M |
| Working Capital | 4.3M | 5.9M | -11M | -15M | -16M | -18M |
| Current Assets | 5.2M | 7.2M | 616K | 627K | 272K | 1.6M |
| Current Liabilities | 901K | 1.3M | 11M | 15M | 17M | 20M |
| Per Share Data | ||||||
| EPS | -5.48 | -4.67 | -0.11 | -0.03 | -0.02 | 0.00 |
| Owner EPS | -6.24 | -2.84 | -0.01 | -0.02 | -0.01 | -0.00 |
| Book Value | 3.08 | 2.16 | 0.03 | 0.03 | 0.03 | 0.02 |
| Cash Flow/Share | -5.65 | -2.50 | -0.01 | -0.01 | -0.00 | -0.00 |
| Dividends/Share | N/A | N/A | N/A | 0.00 | 0.00 | 0.00 |
| Shares Out. | 1.5M | 2.8M | 378.6M | 313.0M | 395.2M | 440.8M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 17.7 | 11.2 | 1.6 | N/A | N/A | 1.7 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -10.3% | -10.3% | -14.8% | N/A | N/A | N/A |
| Market Cap | 81M | 68M | 19M | 0 | 0 | 15M |
| Avg. Price | 9.04 | 3.20 | 0.19 | 0.00 | 0.00 | 0.04 |
| Year-End Price | 5.29 | 2.55 | 0.22 | 0.00 | 0.00 | 0.04 |
Oncotelic Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Oncotelic Therapeutics, Inc. (OTLC) has a return on equity (ROE) of -65.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for Oncotelic Therapeutics, Inc. (OTLC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Oncotelic Therapeutics, Inc. (OTLC) has a book value per share of $0.03, based on its most recent annual SEC filing.